deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00912925

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational, Clinical Study of Recombinant Human Alpha L-Iduronidase In Patients With Mucopolysaccharidosis I

Sponsor: BioMarin/Genzyme LLC

Conditions Hurler-Scheie Syndrome Hurlers Syndrome Mucopolysaccharidosis I
Interventions Placebo rhIDU (recombinant human-Alpha-L-Iduronidase)
Updated 9 times since 2017 Last updated: Mar 19, 2015 Started: Dec 31, 2000 Primary completion: Sep 30, 2001 Completion: Sep 30, 2001
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hurler-Scheie Syndrome and Hurlers Syndrome, this trial is completed. The trial is conducted by BioMarin/Genzyme LLC and has accumulated 9 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioMarin/Genzyme LLC
  • Genzyme, a Sanofi Company
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations